Autosomal Recessive Multiple Pterygium Syndrome
Disease Details
Family Health Simplified
- Description
- Autosomal recessive multiple pterygium syndrome (ARCMS) is a rare genetic disorder characterized by web-like skin folds (pterygia) across joints, restricted movement, growth delays, and distinctive facial features due to mutations in the CHRNG gene.
- Type
- Autosomal recessive multiple pterygium syndrome is transmitted via an autosomal recessive pattern. This means that an individual must inherit two copies of the mutated gene, one from each parent, to express the disease.
- Signs And Symptoms
-
Autosomal recessive multiple pterygium syndrome, also known as Escobar syndrome, is a genetic disorder characterized by various signs and symptoms:
- **Pterygia**: Webbing of the skin at the neck, fingers, knees, and other joints.
- **Contractures**: Joint stiffness and limited movement, often present at birth.
- **Skeletal abnormalities**: Short stature, scoliosis (curvature of the spine), and other bone deformities.
- **Facial features**: Distinctive facial appearance, including downward-slanting eyes, small jaw (micrognathia), and low-set ears.
- **Craniofacial anomalies**: Cleft palate or other abnormalities of the mouth and facial structures.
- **Respiratory issues**: May include difficulty breathing due to chest deformities or other structural problems.
- **Genitourinary anomalies**: In some cases, abnormalities related to the urinary and reproductive systems.
The severity and combination of symptoms can vary widely among affected individuals. - Prognosis
- Autosomal recessive multiple pterygium syndrome is a rare genetic disorder characterized by the presence of multiple web-like skin folds (pterygia) and other congenital anomalies. The prognosis for individuals with this syndrome can vary widely based on the severity of symptoms and associated complications. Some individuals may experience significant physical limitations and require surgical interventions, while others might have milder manifestations. Early diagnosis and supportive care can improve the quality of life.
- Onset
- Autosomal recessive multiple pterygium syndrome typically has an onset at birth.
- Prevalence
- The prevalence of autosomal recessive multiple pterygium syndrome is not well-documented in the literature, and specific population-based data are generally not available. It is considered a rare genetic disorder.
- Epidemiology
- Autosomal Recessive Multiple Pterygium Syndrome primarily affects the formation of skin webs (pterygia) across joints. It's a rare genetic disorder, and the exact prevalence is not well-documented due to its rarity.
- Intractability
- Autosomal recessive multiple pterygium syndrome is considered intractable as there is currently no cure for the condition. Management primarily focuses on addressing symptoms and complications, such as surgical interventions for pterygium and support for associated physical and developmental challenges.
- Disease Severity
- Autosomal recessive multiple pterygium syndrome is characterized by its severity being variable, ranging from mild to severe. This condition often includes features such as webbing of the neck, fingers, and other joints, as well as possible skeletal abnormalities and congenital contractures. The prognosis can depend on the specific manifestations and any associated complications.
- Pathophysiology
- Autosomal Recessive Multiple Pterygium Syndrome (ARCPS) is a congenital disorder primarily characterized by the presence of web-like skin folds (pterygia) at various joints. The condition is caused by mutations in the CHRNG gene, which encodes the gamma subunit of the nicotinic acetylcholine receptor. This receptor is critical for muscle function, and its impairment leads to defective neuromuscular transmission, resulting in decreased fetal movement and abnormal connective tissue development. Consequently, the affected individuals exhibit joint contractures, pterygia, facial anomalies, and other systemic manifestations at birth.
- Carrier Status
- Carriers of autosomal recessive multiple pterygium syndrome have one copy of the mutated gene and typically do not exhibit symptoms of the condition.
- Mechanism
-
Autosomal recessive multiple pterygium syndrome (MPS) is a genetic disorder characterized by the presence of web-like skin folds (pterygia) in various body regions, as well as additional anomalies such as joint contractures, craniofacial abnormalities, and short stature.
### Mechanism:
The syndrome is inherited in an autosomal recessive pattern, which means that two copies of the mutated gene, one from each parent, are required for an individual to be affected. Parents of an individual with an autosomal recessive condition typically carry one copy of the mutated gene but do not show signs and symptoms of the condition.
### Molecular Mechanisms:
The underlying genetic cause of autosomal recessive multiple pterygium syndrome is typically mutations in the CHRNG gene, which encodes the gamma subunit of the nicotinic acetylcholine receptor (nAChR) on muscle cells. This receptor is crucial for the proper transmission of signals from nerve cells to muscles, facilitating muscle contraction. Mutations in CHRNG disrupt the function of nAChR, impairing neuromuscular junction signaling during fetal development. This impairment contributes to the abnormalities seen in muscle and joint development, leading to the characteristic pterygia and other symptoms of the syndrome. - Treatment
-
Autosomal recessive multiple pterygium syndrome (also called Escobar syndrome) is a rare genetic disorder. The treatment is usually symptomatic and supportive, rather than curative. Options may include:
1. **Surgical Interventions**: To correct physical abnormalities such as limb contractures, webbed skin (pterygium), and spinal deformities like scoliosis.
2. **Physical Therapy**: To improve mobility and prevent contractures.
3. **Orthopedic Devices**: To support musculoskeletal function.
4. **Genetic Counseling**: For affected families to understand the condition and its inheritance.
Comprehensive care often involves multidisciplinary teams including geneticists, orthopedists, physical therapists, and other specialists. - Compassionate Use Treatment
-
Autosomal recessive multiple pterygium syndrome (MPS) is a rare genetic disorder characterized by multiple congenital webbed skin folds, joint contractures, and other anomalies. Currently, there are no specific treatments approved for this condition. Treatment approaches focus on managing symptoms and improving quality of life through multidisciplinary supportive care.
1. **Compassionate Use Treatment**: This allows patients with serious or life-threatening conditions to access investigational treatments outside of clinical trials. For MPS, certain experimental drugs or therapies used in similar genetic or musculoskeletal disorders may be provided under compassionate use, but must be closely supervised by healthcare providers and meet specific regulatory requirements.
2. **Off-label Treatments**: Off-label use of medications may be considered by physicians to alleviate symptoms or manage complications of MPS. For example, drugs to manage muscle spasms or pain could be prescribed even though they're not specifically approved for MPS. Physical therapy and surgical interventions are also common off-label approaches to address joint contractures and pterygia (webbing).
3. **Experimental Treatments**: Research into genetic therapies, such as gene editing or gene replacement, is ongoing and might offer future treatment options. Patients may participate in clinical trials investigating these novel therapies, which are experimental and not yet widely available.
Collaborative care involving geneticists, orthopedic surgeons, physical therapists, and other specialists is essential to developing a comprehensive treatment plan for individuals with MPS. - Lifestyle Recommendations
-
For individuals with Autosomal Recessive Multiple Pterygium Syndrome (ARCMS), lifestyle recommendations focus on managing symptoms and improving quality of life. Key strategies include:
1. **Regular Medical Check-ups**: Continuous monitoring by healthcare providers to manage and track symptoms.
2. **Physical Therapy**: To improve and maintain mobility, physical therapy routines may be beneficial.
3. **Occupational Therapy**: Helps in adapting daily activities and promoting independence.
4. **Speech Therapy**: If speech or feeding difficulties are present, therapy can assist in addressing these issues.
5. **Assistive Devices**: Using braces, splints, or walkers to aid in mobility.
6. **Skin Care**: Regular monitoring and care of skin, particularly in areas prone to pterygium formation.
7. **Healthy Diet**: Maintaining a balanced diet to support overall health.
8. **Genetic Counseling**: For affected families, to understand the condition and explore reproductive options.
9. **Support Groups**: Engaging with support groups for emotional support and practical advice.
These recommendations should be tailored to individual needs and coordinated with healthcare providers. - Medication
- There is no specific medication for autosomal recessive multiple pterygium syndrome (ARC-MPS) as it is a genetic disorder primarily managed through supportive and symptomatic treatments. Care typically involves a multidisciplinary approach, including physical therapy, surgical intervention to correct deformities, and routine monitoring to address issues related to airway management, musculoskeletal abnormalities, and other complications. Genetic counseling is also recommended for affected families.
- Repurposable Drugs
- Repurposable drugs for autosomal recessive multiple pterygium syndrome have not been extensively documented. The condition is rare and primarily managed through symptomatic treatments and surgical interventions for specific issues like joint contractures or skin folds. Further research could potentially identify repurposable drugs, but as of now, no specific medications are established for this syndrome.
- Metabolites
- For autosomal recessive multiple pterygium syndrome (ARCMS), there is no specific set of metabolites consistently associated with the condition that have been identified in the literature. This genetic disorder primarily involves mutations in the CHRNG gene, leading to a variety of clinical manifestations including webbing of the skin, joint contractures, and other skeletal anomalies. Metabolite profiling is not a standard diagnostic tool or area of focus for this syndrome.
- Nutraceuticals
- Autosomal Recessive Multiple Pterygium Syndrome (MPS) is a rare genetic disorder characterized by the presence of web-like skin folds (pterygia) and other congenital anomalies. As of now, there are no specific nutraceuticals (dietary supplements with potential medical benefits) known to treat or manage this syndrome effectively. Clinical management mainly focuses on symptomatic treatment and supportive care. It is important for individuals with this condition to consult healthcare professionals for personalized medical advice and potential interventions.
- Peptides
- Autosomal recessive multiple pterygium syndrome (MPS) is a genetic disorder characterized by various congenital anomalies including webbing of the skin, joint contractures, and other skeletal abnormalities. The syndrome is caused by mutations in certain genes, including CHRNG, which encodes the gamma subunit of the acetylcholine receptor. Specific peptides derived from proteins encoded by affected genes may be of research interest for understanding the disease pathology, possibly offering targets for future therapeutic intervention. However, to my knowledge, there are no widely recognized peptide-based treatments currently available for this syndrome. Direct applications of nanotechnology in treating or diagnosing this syndrome are also not yet a standard practice but might be a field of future research.